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Mannich bases are compounds bearing a β-amino carbonyl moiety. They are formed in the 
Mannich reaction that consists of an amino alkylation of an acidic proton placed next to a 
carbonyl functional group by formaldehyde and a primary or secondary amine. Mannich base 
products are known for their curative properties such as anti-inflammatory, antibacterial, 
anticancer, antifungal, anthelmintic, anticonvulsant, analgesic, anti-HIV, antipsychotic, antiviral, 
and antimalarial activities. Further, thiazolidinedione derivatives have shown to be efficacious in 
inflammatory diseases as wide-ranging as psoriasis, ulcerative colitis and non-alcoholic 
steatohepatitis. In light of the above observations, new series of thiazolidine-2,4-dione based 
Mannich base derivatives were synthesized via a simple and catalyst-free procedure involving 
the condensation of thiazolidine-2,4-dione, formaldehyde and secondary amines in DMF solvent. 
The structures of the newly synthesized compounds were confirmed by their IR, 1H-NMR, and 
Mass spectra. The synthesized compounds were tested for their in silico anti-inflammatory 
activity by Docking studies against COX-2 enzyme (PDB: 1CX2). Compounds 4a and 4b 
showed good in silico anti-inflammatory properties comparable to that of standard drug 
Diclofenac and may be considered as promising candidates for the development of new anti-
inflammatory agents. 
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1.  Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment and 
management of inflammation and pain associated with conditions such as osteoarthritis, 
rheumatoid arthritis, post-operative pain, orthopedic injuries, ankylosing spondylitis, gout, 
dysmenorrhea, dental pain and headache (Atzeni et al., 2018; Ong et al., 2007). Non-steroidal 
anti-inflammatory drugs are divided into two categories: non-selective inhibiting both 
cyclooxygenase enzymes COX-1 and COX-2, and selective inhibiting COX-2 enzyme (Brune 
and Patrignani, 2015). Although COX-1 and COX-2 are isoenzymes involved in the same 
physiological pathway converting arachidonic acid (AA) to prostaglandins (PDs)  (Bakhle, 1999; 
Meek et al., 2010), COX-1 isoenzyme is a constitutive enzyme mainly found in the 
gastrointestinal lining with a “house-keeping” role in regulating many normal physiological 
processes in which prostaglandins serve a protective role (Fokunang et al., 2018), though COX-2 
enzyme is facultative, and expressed at the sites of inflammation by pro-inflammatory molecules 
such as interleukin-1 (IL-1), tumor necrosis factor- (TNF-), lipopolysaccharide (LPS), and tissue 
plasminogen activator (TPA) (Fokunang et al., 2018; B Bari and D Firake, 2016) and produces 
the desirable effects of NSAIDs (Zarghi and Arfaei, 2011). For the reasons stated above, long 
term uses of non-selective NSAIDs is not advisable due to their severe gastrointestinal toxicities 
(Rodríguez and González-Pérez, 2005;  Vostinaru, 2017), resulting from their stronger inhibition 
of COX-1 enzyme (Vostinaru, 2017). Examples of NSAIDs that were removed from the market 
due to their toxicities include Vioxx (rofecoxib) pulled from the worldwide market due to its 
increased risk for heart attacks and strokes (Sibbald, 2004); Bromfenac, Ibufenac, and 
Benoxaprofen that were reported to be hepatotoxic (Goldkind, 2006). Therefore, the present 
work intends to search for novel safe and selective COX-2 inhibitors for the management of pain 
and inflammation.  
Thiazolidine-2,4-dione (TZD) derivatives were reported to exhibit diverse pharmacological 
properties such as anti-tubercular (Chilamakuru et al., 2013), antidiabetic, antimicrobial and anti-
cancer (Durai Ananda Kumar et al., 2015). Recently, it was reported that TZD derivatives are 
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potent anti-inflammatory agents (Srivastava et al., 2019). In the study conducted by Zhu et al. 
(2011), TZDs inhibited the release of a variety of inflammatory mediators from human Airway 
Smooth Muscle cells, suggesting their uses in the treatment of asthma. Ceriello (2007) reviewed 
the anti-inflammatory activity of TZDs and found that these compounds act by modulating the 
anti-inflammatory markers such as IL-6, IL-18, CRP, MMP-2, MMP-9. Mohanty et al. (2004) 
evidenced the anti-inflammatory effect of rosiglitazone as a drug of the thiazolidinedione class 
that exerts an anti-inflammatory effect at the cellular and molecular level, and in plasma. In 
addition to these useful properties of thiazolidinedione products; furan and thiophene derivatives 
form a class of compounds with a broad spectrum of biological properties such as antibacterial 
(Holla et al., 1987), anti-allergic, antidepressant, antidiabetic, analgesic and anti-inflammatory 
activities (Mishra et al., 2011).  
Nowadays, in silico molecular docking studies of small molecules to protein binding sites has 
become an increasingly popular approach for the development of new drugs (Berry et al., 2015). 
This is because in silico molecular docking study requires very less time to differentiate from 
many compounds the most probable potent ones with desired biological activities when 
compared with traditional laboratory experiments (Naim et al., 2018; Afriza et al., 2018). In view 
of the above prominent properties of thiazolidinedione, furan and thiophene derivatives and rapid 
with higher precision of in silico docking studies, novel series of compounds incorporating both 
thiazolidine-2,4-dione and furan/thiophene moieties in one Mannich base molecule that might 
display synergetic and enhanced biological activities were synthesized, characterized and 
evaluated for their in silico COX-2 inhibitory activity.  
2. Material and methods 
2.1. Material 
The innovative DTC-967A apparatus was used to determine the melting points of the new 
compounds and are uncorrected. The IR-spectra (in KBr pellets) were recorded on Shimadzu FT-
IR Prestige-21 spectrophotometer and are expressed in cm-1. The mass spectra were recorded on 
Shimadzu LC-MS-8030 mass spectrophotometer operating at 70 eV. A Bruker AVANCE II 400 
MHz instrument was used to record 1H-NMR spectra in CDCl3 as solvent and TMS as an 
internal standard. 
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2.2. Chemistry method 
Thiazolidine-2,4-dione (1) was synthesized by the cyclocondensation of thiourea with 
monochloroacetic acid in acidified water solvent (Kar et al., 2014). Knoevenagel condensation of 
thiazolidine-2,4-dione (1) with furan/thiophene-5-carbaldehyde (2) in ethanol solvent containing 
a catalytic amount of piperidine afforded the key intermediate: furfurylidene/thienylidene 
thiazolidine-2,4-dione (3) prepared according to Ha et al. (2012). Novel Mannich base products 
(4) were synthesized by reacting compounds (3) with formaldehyde and secondary amines: 
piperidine, morpholine or N-methylpiperazine (Scheme 1) in DMF solvent as given in the 
general procedure. The completion of the reaction, as well as the purity of the products (4), were 
checked by TLC using silica gel plates (Merck) with hexane:ethylacetate (6:4) as mobile phase. 
 
Scheme 1: Synthesis of Mannich base derivatives of thiazolidinedione 
 
Synthesis of 5-(furan-2/thiophen-2-ylmethylene)thiazolidine-2,4-dione-based Mannich 
bases (4a-e): General procedure 
 
Furfurylidene/thienylidene thiazolidine-2,4-dione (3) (0.01 mol) and formaldehyde (40%, 1.5 
mL) were added in 100 mL Erlenmeyer flask containing 10 mL DMF. Using a magnetic stirrer, 
the mixture was stirred at room temperature for 20 min. An appropriate secondary amine (0.01 
mol): piperidine / morpholine / N-methyl piperazine was then added, and the resulting mixture 
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was further stirred at room temperature for 6 hours to precipitate Mannich base products that 
were collected by filtration, washed with cold water, dried and recrystallized from ethanol. 
2.3. Molecular Docking Studies 
In silico docking study was performed according to Rizvi et al. (2013) to predict interactions of 
newly synthesized compounds (4a-e) with the target COX-2 enzyme's active site. The crystal 
structure of COX-2 (PDB code: 1CX2) was downloaded from RCSB Protein Data Bank 
(http://www.rcsb.org) as 1CX2.PDB (gz). It was then processed using Discovery Studio Biovia 
2020 suite (Dassault Systèmes, San Diego, California, USA) in which protein inhibitor SC558, 
all water molecules, unwanted heteroatoms and similar chains B, C and D were deleted to 
generate the file saved as 1CX2.PDB. This file was further processed by adding polar hydrogen 
atoms and Kollman Charges to the individual protein atoms with Auto Dock Tool (ADT) 
software to get 1CX2.PDBT file required for Autogrid and AutoDock (Huey and Morris, 2008); 
Rizvi et al., 2013). 
The Marvin Sketch software (Marvin suite 20.11.0) was used for drawing and energy 
minimization of each ligand structure (4a-e) to generate ligand.PDB. The ADT was then used to 
process these ligands in which nonpolar hydrogens were combined, Gasteiger changes and 
rotatable bonds were added and generated ligand.PDBQT format needed by Autogrid and 
Autodock (Rizvi et al., 2013; Morris, 2012). Autogrid parameters were set using ADT and a 
docking grid box was built with 40, 40, and 40 points in X, Y and Z dimensions with X=31.594, 
Y=24.653, and Z=12.650  as the position of the active site to generate a.GPF file. A docking 
parameter file a.DPF was prepared using the Lamarckian genetic algorithm 4.2 search method 
implemented in AutoDock 4.2 software integrated within Auto Dock Tools version 1.5.6 (ADT; 
Scripps Research Institute, La Jolla, San Diego, USA). The receptor was kept rigid, ligands were 
allowed to be flexible and all docking parameters were set to default. The molecular docking was 
performed on Microsoft windows 10, 64-bit laptop using Cygwin software. The docking results 
were analyzed by Discovery Studio Biovia 2020 suite software. 
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3.  Results and discussion 
3.1. Chemistry 
The structures of newly synthesized compounds 5-(furan-2/thiophen-2 ylmethylene)thiazolidine-
2,4-dione-based Mannich compounds (4a-e) were confirmed by their IR, 1H-NMR, and mass 
spectra. Other data that characterize the newly synthesized compounds are given in Table 1. 








Mol. Wt Chemical structure 





















The table above gives the melting point: M.P (oC), molecular formula, molecular weight (Mt), 
and the chemical structure of the newly synthesized compounds 4a-4e. The results from the 
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above table show that the newly synthesized compounds were formed in a good yield ranging 
from 68% to 82% with molecular weight between 292 to 310. 
 
The IR spectrum of 5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-2,4-dione (4a) 
(Figure 1) showed prominent bands at 3089 cm-1 and 2964 cm-1 for C-H stretching frequencies. 
The bands at 1645 cm-1 and 1589 cm-1 are attributed for C=O stretching frequencies, while the 
C-O band appeared at 1273 cm-1 stretching frequency.   
 
 
Figure 1: The IR spectrum of 5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-2,4-
dione (4a) 
 
The formation of Mannich base products (4a-e) from compounds (3) was further confirmed by 
their 1H NMR spectra. As a typical example, in the 1H-NMR (400 MHz, CDCl3) spectrum of 5-
(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-2,4-dione (4a) (Figure 2) the 
protons at the 4th position of piperidine moiety labelled as HA appeared as a quintet at δ 1.33-1.39 
ppm integrating for two protons. A quintet signal seen at δ 1.52-1.58 ppm is due to the resonance 
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of four protons (HB) located at the 3
rd position of piperidine moiety. The four protons (HC) from 
the 2nd position of the piperidine group resonated as a triplet at δ 2.59-2.62 ppm while methylene 
N-CH2-N protons (HD) came into resonance as a singlet at δ 4.69 ppm integrating for two 
protons. One proton (HG) at the 4
th position of furan ring come into resonance as a triplet at δ 
6.57-6.58 ppm, whereas a doublet seen δ 6.77-6.78 ppm (J = 3.48 Hz) resulted from the 
resonance of a proton (HF) located at the 3
rd position of furan ring. The CH=C proton (HE) 
resonated as a singlet at δ 7.62 ppm, and a proton (HI) at 5
th position of furan ring appeared as a 
doublet at δ 7.66-7.67 ppm (J = 1.64 Hz).  
 
 
Figure 2: 1H NMR spectrum of 5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-
2,4-dione (4a). 
The mass spectra further confirmed the structures of the new compounds (4a-e). In a typical 
example, the mass spectrum of 5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-
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2,4-dione (4a) (Figure 3) showed molecular ion peak at m/z = 292 (M+) which is in conformity 
with its molecular formula C14H16N2O3S.  
 
 
Figure 3: Mass spectrum of of 5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-
2,4-dione (4a) 
 
The spectral data of other newly synthesized compounds prepared according to the general 
procedure presented in section 2.2 are given below: 
 
4b) 3-(Piperidin-1-ylmethyl)-5-(thiophen-2-ylmethylene)thiazolidine-2,4-dione  
 
IR (KBr, γ/cm-1): 3074, 2985 (C-H stretch), 1633, 1573 (C=O stretch), 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 1.34-1.40 (quintet, 2H at 4
th position piperidine), 1.52-1.58 (quintet, 4H at 3rd 
position of piperidine), 2.60-2.63 (t, 4H at 2nd position of piperidine), 4.71 (s, 2H, N-CH2-N), 
7.17-7.20 (t, 1H, furan-4H), 7.39-7.40 (d, J=3.64 Hz, 1H, furan-3H), 7.64-7.66 (d, J=5.08 Hz, 
1H, furan-5H), 8.04 (s, 1H, C=CH). LC-MS (m/z): 309 (M+ + 1).  
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4c) 3-(Morpholinomethyl)-5-(thiophen-2-ylmethylene)thiazolidine-2,4-dione  
IR (KBr, γ/cm-1): 3111, 2964 (C-H stretch), 1651, 1589 (C=O stretch), 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 2.66-2.68 (t, 4H adjacent to N-morpholine), 3.66-3.68 (t, 4H adjacent to O-
morpholine), 4.70 (s, 2H, N-CH2-N), 7.18-7.21 (t, 1H, furan-4H), 7.40-7.41 (d, J=3.68 Hz, 1H, 
furan-3H), 7.66-7.67 (d, J=5.04 Hz, 1H, furan-5H), 8.06 (s, 1H, C=CH). LC-MS (m/z): 310 
(M+).  
 
4d) 5-(furan-2-ylmethylene)-3-((4-methylpiperazin-1-yl)methyl)thiazolidine-2,4-dione  
 
IR (KBr, γ/cm-1): 3057, 2978 (C-H stretch), 1649, 1587 (C=O stretch), 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 2.25 (s, 3H, N-CH3), 2.41 (s, 4H of piperazine moiety), 2.72 (s, 4H of 
piperazine moiety), 4.73 (s, 2H, N-CH2-N), 7.18-7.20 (t, 1H, furan-4H), 7.39-7.40 (d, J=3.72 Hz, 
1H, furan-3H), 7.65-7.66 (d, J=5.00 Hz, 1H, furan-5H), 8.03 (s, 1H, C=CH). LC-MS (m/z): 323 
(M+).  
4e) 5-(furan-2-ylmethylene)-3-(morpholinomethyl)thiazolidine-2,4-dione  
 
IR (KBr, γ/cm-1): 3082, 2985 (C-H stretch), 1637, 1577 (C=O stretch), 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 2.65-2.68 (t, 4H adjacent to N-morpholine), 3.66-3.68 (t, 4H adjacent to O-
morpholine), 4.68 (s, 2H, N-CH2-N), 6.58-6.59 (m, 1H, furan-4H), 6.78-6.79 (d, J=3.56 Hz, 1H, 
furan-3H), 7.64 (s, 1H, C=CH), 7.64-7.68 (d, J=4.52 Hz, 1H, furan-5H). LC-MS (m/z): 294 
(M+).  
The plausible mechanism for the formation of the above new Mannich base products probably 
involved the formation of an alcohol intermediate (OH-intermediate) rather than imine from the 
reaction between thiazolidine-2,4-dione derivatives (3) with formaldehyde. This intermediate 
product then condensed with secondary amines to furnish the title compounds (4) in the reaction 
that has not required a catalyst (Scheme 2).  
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Scheme 2: Mechanism for the formation of Mannich bases (4a-e) 
3.2. Molecular Docking Study 
In silico anti-inflammatory activity of compounds 4a-e was undertaken by studying the binding 
and inhibition effects of ligands (4a-e) to the target COX-2 protein (PDB code: 1CX2) in which 
the co-crystallized structure SC-558 was carefully removed using Discovery studio 2020 suite. 
The docking results of the synthesized compounds (4a-e) and diclofenac used as the reference 
drug are presented in Table 2.  









No. of      
H-bonds 
H-Bond 
4a -7.61 2.65 1 A:ARG120:HH::UNK0:O 
4b -7.59 2.75 0 - 
4c -6.64 13.53 1 A:TYR385:HH::UNK0:O 
4d -6.72 11.81 0 - 
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4e -6.95 8.03 1 A:ARG120:HH::UNK0:O 
Diclofenac -7.63 2.53 1 A:ARG120:HH::UNK0:O 
 
The above results showed that two compounds 4a and 4b displayed good binding energy of         
-7.61 kJ mol-1 and -7.59 kJ mol-1 respectively, which are comparable to the reference drug 
diclofenac with -7.63 kJ mol-1. In addition to one conventional hydrogen bond interaction 
between the oxygen atom of furan moiety in the compound 4a with NH of ARG 120 and one 
carbon-hydrogen bond between the nitrogen atom of piperidine moiety with a CH group of VAL 
523, the observed high binding affinity of compound 4a has been attributed to strong 
hydrophobic interactions between 4a ligand with VAL 116, VAL 349, LEU 359, LEU 531, MET 
522 and ALA 527 amino acids that maximized its interactions with the target binding site 
(Figure 4a and 4b).  
 (a)  (b)    
Figure 4(a): Docked complex between the protein 1CX2 and ligand 4a; Figure 4(b): 
Interacting residues between the protein 1CX2 and ligand 4a. The hydrogen bonds between 
one of the O-atoms of the ligand with ARG 120 is shown in green dotted line. 
 
The 1CX2-Diclorofenac complex is given in Figure 5(a) and the interacting residues in the 
same complex are shown in Fig 5(b).  Diclofenac displayed one conventional hydrogen bond 
between the oxygen atom of the ligand with NH of ARG 120, and also showed strong 
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hydrophobic interactions with VAL 349, VAL 523, LEU352 and ALA 527 amino acids of the 
target active site.  
(a) (b) 
Figure 5(a): Docked complex between protein 1CX2 and diclofenac ligand; Figure 5(b): 
Interacting residues in 1CX2-Diclofenac complex. The hydrogen bond between one of the O-
atoms of the ligand with ARG 120 is shown in green dotted line. The observed results are in line 
with Mousa et al. (2019) experiment in which Diclofenac inhibited the 1CX2 enzyme by binding 
on ARG 120. Furthermore, molecular docking study results showed that each ligand molecule 
displayed its own conformation, related to its IR spectrum that has fitted within the active site to 
some extent. As a typical example, the IR spectrum of compound 4a showed the IR band at 1273 
cm-1 for C-O-C (stretching) of the furan moiety. This furan-oxygen atom displayed one H-bond 
with ARG 120 of the 1CX2 target protein. However, compound 4b which is lacking such a C-O-
C group of atoms did not display such IR band, hence unable to display any hydrogen bond with 
the protein active site. 
4. Conclusion 
We successfully achieved the synthesis of novel series of thiazolidine-2,4-dione-based Mannich 
base bearing furan/thiophene moiety (4a-e) in a reaction that did not require any acidic catalysts. 
In silico docking studies of compounds (4a-e) on particular cyclooxygenase COX-2 enzyme 
(PDB ID: 1CX2) have been evaluated in comparison with Diclofenac used as a reference drug. 
The compounds 4a (5-(furan-2-ylmethylene)-3-(piperidin-1-ylmethyl)thiazolidine-2,4-dione) 
and 4b (3-(Piperidin-1-ylmethyl)-5-(thiophen-2-ylmethylene)thiazolidine-2,4-dione) displayed 
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comparable docking energy to that of standard drug Diclofenac, and the present molecular 
docking studies suggested that these compounds 4a and 4b are candidate ligands for restoring 
inflammation and pain in conditions such as osteoarthritis, rheumatoid arthritis.  
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